The Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) pathway mediates cellular responses to different growth signals and is frequently deregulated in cancer. There are three Raf kinases-A-Raf, B-Raf, and C-Raf; however, only B-Raf is frequently mutated in various cancers. The most common B-Raf mutation involves a substitution of a glutamic acid residue to a valine moiety at codon 600. Subsequently, the MAPK pathway is constitutively activated, even in the absence of any growth signals. In this chapter, we will discuss new patents and patent applications related to inhibitors of the Ras/Raf/MEK/ERK pathway and some recent clinical trial results.
INTRODUCTION
The Ras/Raf/MEK/ERK signaling pathway regulates the expression of a large number of proteins involved in the control of cell proliferation, differentiation, and apoptosis. In response to the binding of growth factors, cytokines, and hormones to cell surface receptors [1, 2] , the level of Ras-guanosine triphosphate thought to be at 599) within the kinase domain. B-Raf mutations have been identified in a wide variety of human cancers, such as melanomas, ovarian borderline tumors, sporadic colorectal carcinomas, and thyroid carcinomas Table 1 [11] [12] [13] [14] [15] . The data were extracted from "The Catalogue of Somatic Mutations in Cancer" (COSMIC) database [16] . The B-Raf mutated protein, referred as BRaf V600E , has increased kinase activity compared to wild-type B-Raf [11] . BRaf V600E activates the downstream MEK/ERK signaling pathway independently of Ras-GTP and its expression is required to maintain the proliferative and oncogenic characteristics of B-Raf V600E -expressing human tumor cell lines [14] [15] [16] . Recent evidence suggests that mutant B-Raf also causes chromosome instability via phosphorylation of Mps1; up-regulates GLUT-1 which enhances glucose metabolism in tumor cells; and causes DNA strand breakage and damage [17, 18] . Mutated B-Raf V600E is also no longer repressed by SPRY2-an inhibitor of MAPK signaling in epithelial and fibroblast cell lines [19] which only binds to wild-type B-Raf to initiate the inhibition of MEK/ERK signaling, but will not bind to B-Raf V600E [20] . Thus, specifically targeting the mutated B-Raf V600E protein without inhibiting the wild-type B-Raf is one of the goals of anti-cancer drug development to improve anti-tumor cell activities while minimizing toxicity. . The IC 50 of PLX4032 is the lowest among a panel of 65 non-Raf kinases tested [21] . This small molecule was identified from Plexxikon's proprietary Scaffold-based Drug Discovery platform [22] . Most of the other kinases tested have a more than 100-fold higher IC 50 , except Brk (also known as PTK6), which has an IC 50 of 240nmol/L. PLX4032 specifically targets B-Raf V600E ; however, inhibition of tumor cell proliferation and MEK phosphorylation was only observed in colorectal tumor cell lines harboring B-Raf V600E but not wild-type BRaf [23] . Clinically, this compound has had profound effects on melanoma patients who previously had a very grim prognosis. Several Phase I-III clinical trials have evaluated the efficacy of vemurafenib, especially in the setting of melanoma. In one hundred and thirty two patients with previously treated BRaf V600E -mutant metastatic melanoma enrolled in a multicenter Phase II trial of vemurafenib, overall response rate was 53% with a median duration of response of 6.7 months and median overall survival of 15.9 months [24] . A randomized Phase III trial also showed improved overall and progression-free survival in melanoma as a first-line agent when compared to dacarbazine in 675 patients with metastatic melanoma [25] . At 6 months, 84% of the vemurafenib group was still alive, compared to 64% of the dacarbazine group. This data led to FDA approval of vemurafenib for use in B-Raf V600E -positive melanoma in 2011. While highly efficacious in melanoma, unfortunately, the same activity has not been observed in colorectal carcinoma. In a Phase I study of 21 patients with B-Raf V600E -positive metastatic colorectal carcinoma, there was only one partial response and 4 minor responses [26] . Toxicity of vemurafenib is generally mild: The most common adverse events in the clinical trials were rash, nausea, diarrhea, arthralgia, photosensitivity, fatigue, and alopecia. However, paradoxical activation of the Ras pathway leads to formation of keratoacanthomas and squamous cell carcinomas in these patients-a significant side effect which requires routine screening [27] .
DRUGS TARGETING THE RAS/RAF/MEK/ERK PATHWAY CURRENTLY IN CLINICAL TRIAL
RAF265 (CHIR-265; Novartis Pharmaceuticals, Basel, Switzerland), an orally bioavailable small molecule, is a potent inhibitor of Raf with a highly selective profile and is a derivative of benzazoles (Chiron, a subsidiary of Novartis) [28] . RAF265 binds and inhibits Raf kinases, which results in apoptosis and reduction in tumor proliferation. In addition, RAF265 inhibits VEGFR-2, thereby disrupting tumor angiogenesis [29] . A preclinical study found that RAF265 inhibits all three isoforms of Raf, as well as B-Raf V600E , with high potency. RAF265's antitumor activity has also been seen in preclinical xenograft models [30] . In a Phase I firstin-human trial of RAF265 in 76 patients with advanced melanoma, overall response rate was 16% for patients with B-Raf mutations and 13% for wildtype/unknown mutations [31] . A major side effect was dose-limiting hematologic toxicity. Phase II trials are currently ongoing.
Sorafenib (BAY43-9006; Bayer Schering Pharma, Pittsburgh, PA) is a bi-aryl urea which was initially identified as an adenosine triphosphate competitive inhibitor of the C-Raf kinase (from now on referred to as the Raf1 kinase). In vitro biochemical assays confirmed that sorafenib is a potent in vitro inhibitor of the Raf1 kinase (IC 50 = 6nM) [32] . Sorafenib has also been shown to inhibit Raf1 and, thus, tumor cell proliferation and tumor growth in several human tumor xenograft models [33] . Subsequently, sorafenib was shown to have multikinase inhibition activities, which is likely responsible for sorafenib's clinical efficacy [32] . Sorafenib targets two kinase classes known to be involved in both tumor proliferation and angiogenesis [34] . These include the enzyme Raf kinase, a critical component of the Ras/Raf/MEK/ERK signaling pathway; and the VEGFR-2/platelet-derived growth factor receptor (PDGFR)-beta signaling cascade, thereby blocking tumor growth and angiogenesis. It also inhibits c-Kit and fibroblast growth factor receptor 1 (FGFR1) [35] . Sorafenib has been evaluated as a single-therapy agent and in combination with various chemotherapy drugs in a number of clinical trials [36] [37] [38] . In a study that compared sorafenib with placebo, treatment with sorafenib prolonged progressionfree survival in patients with advanced clear-cell renal cell carcinoma for whom previous therapy had failed. Subsequently, sorafenib was approved by the U.S. Food and Drug Administration for the treatment of advanced renal cell carcinoma and advanced hepatocellular carcinoma and has since performed well in Phase III trials [39] . Over 200 clinical trials are currently ongoing, and a few studies are investigating the correlation between clinical response and B-Raf mutation status. Interestingly, the most clinically beneficial function of sorafenib arises from its antiangiogenicity; the Raf inhibition seems less potent, as evidenced by Phase II and III trials in melanoma patients, where sorafenib had limited efficacy even when response was analyzed according to B-Raf mutation status [37, 40] .
Regorafenib (BAY73-4506; Bayer Schering Pharma, Pittsburgh, PA) is a more potent derivative of sorafenib formed by adding a fluorine atom to the phenyl group. Similar to sorafenib, it inhibits multiple kinases, including VEGFR 1-3, TIE2, PDGFR, FGFR1, cKIT, RET, and B-Raf, with an IC 50 ranging from 4 to 311nM [41] . In xenograft models, it inhibited tumor growth in glioblastoma, breast, renal cell, and colorectal carcinomas [41] . A recent Phase I trial demonstrated acceptable activity and toxicity in 53 patients with solid tumors, three of 47 patients achieved a response and the most common side effects were dermatologic manifestations, hypertension, and diarrhea [42] . In Phase II trials, regorafenib has performed well: In pretreated gastrointestinal stromal tumors (GIST), 19 of 22 patients were without progression after 4 cycles [43] . In a Phase III trial in patients with metastatic colorectal cancer, a statistically significant benefit in progression-free survival (PFS) and overall survival (OS) was observed in the regorafenib group vs. supportive care, such that the control group was allowed crossover into regorafenib treatment [44] . Phase II and III trials are ongoing.
XL281 (Exelixis, San Francisco, CA) is an orally active small molecule with potential antineoplastic activity that specifically inhibits Raf kinases, including Raf1, B-Raf, and activated B-Raf V600E [45] . XL281 has shown activity in tumor xenograft models [46] . A Phase I clinical trial concluded that XL281 had acceptable activity and toxicity in adult patients with solid tumors [47] ; however, there are currently no open clinical trials evaluating this compound.
AZD6244 (ARRY-142886, Selumetinib; AstraZeneca, London, England) is an oral, highly selective allosteric inhibitor of MEK [48] . AZD6244 was the second MEK inhibitor to enter clinical trials after the first MEK inhibitor, CI-1040, demonstrated poor clinical efficacy. However, the encouraging safety profile of CI-1040 provided the momentum to search for more potent analogues [49] . AZD6244 is a benzimidazole derivative with reported nanomolar activity against the purified MEK1 enzyme [50] . Through a series of studies using preclinical cell cultures and animal models, it was shown that AZD6244 suppresses the growth of melanoma cells through the induction of cytostasis, but AZD6244 has a limited ability to induce apoptosis or block angiogenesis [51] . In a Phase I study in patients with advanced cancer, AZD6244 was well tolerated with demonstrable clinical activity [35] , with rash being the most common dose-limiting toxicity. This prompted several Phase II studies which have now evaluated AZD6244. Overall, AZD6244 has displayed modest antineoplastic activity in iodine-refractory papillary thyroid cancer [52] and metastatic biliary cancer [53] , while results in hepatocellular cancer patients were less robust [54] . In the papillary thyroid patient population, patients with B-Raf V600E mutations had longer median PFS [52] . Phase II studies have also compared singleagent AZD6244 to other antineoplastics, and have found that AZD6244 is effective but not superior to standard chemotherapeutics. Compared to temozolomide in 200 advanced-stage melanoma patients [55] , AZD2644 was active, but there was no difference in progression free survival between the two drugs. However, 5 of 6 partial responders to AZD6244 had B-Raf mutations. Compared to permextred in 84 heavily-pretreated patients with advanced non-small cell lung cancer, AZD6244 was again active, but there was no difference in disease progression between both groups [56] . Finally, in patients with advanced pancreatic cancer who had progressed through treatment with gemcitabine, there was no difference in overall survival in patients treated with AZD6244 compared to capecitabine [57] . Common side effects of AZD6244 in the above clinical trials included nausea, rash, peripheral edema, and diarrhea.
DERIVATIVES OF INITIAL LEAD COMPOUNDS IMPROVE SPECIFICITY AND POTENCY
Patents issued and patent applications published in recent years have identified numerous lead compounds that target Raf, MEK, or multiple tyrosine kinases [58] [59] [60] [61] [62] [63] [64] [65] [66] . Many of these compounds are derived from aromatic heterocyclic compounds, such as imidazole, quinazoline, phenethylamide, malonamide, and benzazoles Tables 3 and 4. Using these compounds as the initial scaffolds for modifications, more potent inhibitors have been identified. For example, to improve the bioavailability and potency of CI-1040 [67] , a derivative, PD0325901, was developed [68] . PD0325901 was derived by replacing the cyclopropylmethoxy group with a (R)-2,3-dihydroxypropoxy group and replacing the 2-chloro substituent with a 2-fluoro group on the second aromatic ring of CI-1040 Fig. (2A) . Such small structural changes resulted in a more than 100-fold target potency as reflected by PD0325901's ability to inhibit both purified MEK, as well as cellular activation of MAPK, at concentrations in the nanomolar range. Moreover, the activity of PD0325901 has also been observed against a panel of B-Raf V600E xenografts [69] . A Phase I trial investigated PD0325901 in 13 patients with metastatic melanoma, colorectal, or breast cancer at doses of 20 mg and 15 mg orally twice daily [70] . Although one patient had a complete response and 5 had stable disease, the study was terminated early due to an unexpected high incidence of musculoskeletal and neurological toxicity. However, another Phase I trial (NCT01347866) is examining a PI3K/mTOR inhibitor in combination with PD0325901 or irinotecan. Given its untoward neurologic side effects, modifications of PD0325901 have led to the development of two new more specific, stable compounds: RO4987655 (CH4987655; Hoffman-La Roche, Basel, Switzerland) and TAK-733 (Takeda Pharmaceutical, Osaka, Japan), both of which are less susceptible to hydrolyzation than PD0325901. TAK-733 is a novel 5-phenylamino-8-methylpyrido [2,3-d] pyrimidine-4,7(3H,8H)-dione with a bicyclic pyridopyrimidinione core and a dihydroxypropane side chain. It is highly selective, performing in the nanomolar range with an IC 50 of 3.2nM against MEK1/2, and antitumor activity in xenograft models of melanoma, non-small cell lung, breast, pancreatic, and colorectal carcinoma [71] . A Phase I study is underway evaluating TAK-733 in advanced nonhematologic malignancies (NCT00948467). RO4987655 was developed with a unique 3-oxo-[1,2]oxazinan-2-ylmethyl group at the 5-position, and inhibits MEK at an IC 50 of 5nM. In xenograft models with colorectal, non-small cell lung, and pancreatic carcinomas, RO4987655 potently inhibited MEK activity [72] . 2011 [124] In continuing to improve specificity and circumvent undesirable neurologic side effects, BAY86-9766 (RDEA119, refametinib; Bayer Schering Pharma, Pittsburgh, PA) was developed. It binds noncompetitively to MEK1/2 adjacent to the Mg-ATP binding region and inhibits MEK1/2 activity at an IC 50 of 19 and 47nM, respectively [73] . It inhibits colorectal carcinoma and melanoma tumor xenografts without neurologic penetration [73] , and Phase I trials have confirmed safety. A Phase II trial evaluating refametinib in combination with gemcitabine in pancreatic cancer patients is ongoing (NCT01251640). A derivative of imidazole was identified from the SmithKline Beecham compound bank as a submicromolar inhibitor of B-Raf [74, 75] . Structural modification of imidazole resulted in the formation of GSK2118436 (SB-590885, dabrafenib; SmithKline Beecham, Middlesex, England), which is a triarylimidazole derivative with a 2,3-dihydro-1H-inden-1-one oxime substituent Fig. (2B) . Is a potent and extremely selective inhibitor of the B-Raf kinase in the nanomolar range [76] . Unlike the multikinase inhibitor BAY43-9006, dabrafenib seems to target cells that express oncogenic B-Raf [77] . A Phase I trial displayed encouraging results in melanoma patients, with 24 of 32 patients with a partial response and 2 patients exhibiting a complete response. Median progression-free survival was over 7 months [78] . Perhaps most excitingly, preliminary results from a Phase II clinical trial (NCT01266967) in metastatic melanoma with brain involvement revealed a 90% response rate. Clinical trials are now examining this compound in the setting of lung and thyroid cancer, and B-Raf mutant-positive tumors.
Further modification of GSK2118436 has also resulted in the identification of a series of furan-based derivatives with enhanced central nervous system penetration and B-Raf inhibitory activity [79, 80] . Such B-Raf inhibitors may be of value in the treatment of specific types of pediatric gliomas (e.g., low-grade astrocytomas), as MAPK pathway activation was discovered in low-grade astrocytomas as a result of B-Raf gene duplication [81] . GSK1120212 (Trametinib) was created with a pyrido-pyrimidin core and an N-phenylacetamide substituent. It inhibits MEK1/2 enzymatic activity at an IC 50 of 10nM, with a particularly long circulating half-life and p-ERK suppression for over 24 hours. It also displayed potent activity in melanoma and colorectal cancer xenograft models [82] , which has led to several Phase I trials confirming its safety and efficacy. The first Phase I trial investigated trametinib in 84 patients, and in 20 evaluable melanoma patients of known B-Raf status there were 5 partial responses, three of whom have stayed ≥ 30 weeks on study [83] . There are now several Phase II studies. Preclinical testing yielded effective and specific MEK1/2 inhibition in multiple myeloma and colorectal tumors [84, 85] , which prompted several clinical trials. A Phase I trial in advanced solid tumors with AS703026 resulted in two confirmed partial responses prior to reaching the maximum tolerated dose [86] . Common side effects were asthenia, diarrhea, skin reactions, nausea, and vomiting. There are currently 6 Phase I or combination Phase I/II trials open evaluating the compound as a single agent or in combination with other antitumor drugs.
By using a structure-guided discovery approach [22] , a small-molecule 7-azaindole was found to bind the ATP-binding site of kinases with weak affinity. Subsequently, a group of mono-and disubstituted 7-azaindoles with increased affinity was synthesized. Screening of these compounds revealed a set of compounds containing a difluoro-phenylsulfonamide substructural motif that demonstrated excellent potency for oncogenic B-Raf. Co-crystallization of these compounds with engineered forms of B-Raf
V600E
and wild-type B-Raf provided co-crystal structures for subsequent optimization chemistry, which led to the discovery of propane-1-sulfonic acid [3-(5- 
kinase activity in vitro, with an IC 50 of 13 nM, which is 10-fold lower than the concentration needed to inhibit wild-type B-Raf. Furthermore, in B-Raf V600E -dependent tumor xenograft models, oral PLX4720 significantly reduced tumor growth and even caused tumor regression, without evidence of toxicity [87] . PLX4032 is a structurally distinct analog of PLX4720. PLX3603, another derivative of PLX4032, is under evaluation in a Phase I clinical trial. MEK162 (ARRY162, Novartis Pharmaceuticals, Basel, Switzerland) is another new oral MEK inhibitor, initially developed for rheumatoid arthritis, which functions through noncompetitive allosteric inhibition against MEK1/2 (IC 50 12nM) and ERK (IC 50 11nM), as well as IL-1, TNF, and IL-6, with activity against pancreatic, colorectal, and non-small cell lung carcinoma, as well as fibrosarcoma [88] . Phase I studies have been completed with tolerable efficacy and toxicity, and several Phase I/II studies are examining its efficacy in combination with other targeted agents (AMG479, an IGF-1R inhibitor, NCT01562899; RAF265, NCT01352273; BEZ235, a PIK/mTOR inhibitor, NCT01337765). Another Phase II trial is investigating MEK162 as a single agent in melanoma (NCT01320085). 
CURRENT & FUTURE DEVELOPMENTS
Targeting the Ras/Raf/MEK/ERK cascade has provided novel opportunities for the development of new anti-cancer drugs that are less toxic than conventional chemotherapeutic drugs. Several promising compounds have been developed to inhibit the activities of B-Raf, MEK, or multiple kinases Fig. (3) . Continued efforts aimed at structural optimization of the chemical scaffolds of compounds such as imidazole and quinazoline have resulted in more potent inhibitors in nanomolar or even subnanomolar ranges [89] [90] [91] [92] . Multikinase inhibitors or B-Rafspecific inhibitors can have been developed from similar chemical scaffolds. For example, derivatives of quinazoline may have multiple tyrosine kinase [93] or BRaf-specific [94] inhibition activities. (E)-α-benzylsulfonyl chalcone derivatives have also been identified as B-Raf inhibitors [95] .
While MEK inhibitors harbor anticancer activity, they have generally not outperformed standard chemotherapy in Phase II and III trials. However, more specific compounds which preferentially target B-Raf mutations, such as SB-590885 and PLX4032, have had a profound effect on melanoma patients, extending lifespan in B-Raf V600E -positive patients by an average of seven months [24] . Targeting specific oncogenic mutated kinases will theoretically allow specific inhibition or elimination of tumor cells, depending on the mutated ki ph re inhibition was less effective than in melanoma, Prahallad and colleagues [100] discovered that dual inhibition with PLX4032 and an EGFR inhibitor (cetuximab, gefitinib, or erlotinib), overcame B-Raf-mediated resistance in colorectal carcinoma cell lines. Cotargeting MEK, the IGF-1 receptor, and PI3K in combination with B-Raf inhibition has also overcome resistance preclinically [101] . Indeed, several patents combining MEK and B-Raf inhibition with other agents have recently emerged [102] [103] [104] [105] , as have clinical trials. Preliminary results from a Phase I/II trial combining the MEK 1/2 inhibitor GSK1120212 with the B-Raf inhibitor GSK2118436 in patients with stage IV previously-untreated melanoma revealed an objective response rate of 77%, and a decrease in the incidence of keratoacanthomas [106] .
Multikinase inhibitors such as sorafenib and regorafenib are therefore attractive owing to their multitarget activity. Fortuitously, sorafenib was found to have activity against multiple protein kinases, yet the original goal in developing sorafenib was to identify a Raf inhibitor. It remains uncertain whether Raf inhibition alone provides adequate clinical efficacy. Therefore, future clinical trials of more specific and potent Raf kinase inhibitors are warranted. The clinical success of highly selective protein kinase inhibitors, in particular monoclonal antibody-based drugs (e.g., trastuzumab and bevacizumab) [107, 108] , demonstrates that there is clinical value for both highly selective and multipletarget inhibitors.
Along the same lines, additional interest has developed in heat shock protein 90 (Hsp90) inhibitors in targeting B-Raf and attenuating resistance. Hsp90 is a "chaperone" molecule for proteins such as HER2, EGFR, mutant ER, HIF1α, Raf-1, AKT and mutant p53, the inhibition of which blocks several signaling pathways [109] . It also specifically binds mutant but not wild-type B-Raf, and early evidence suggests that Hsp90 inhibitors may overcome drug resistance [110] . While a clinical trial with the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in melanoma patients yielded no objective clinical responses [111] , novel non-benzoquinone small molecule Hsp90 inhibitors may prove more effective with their improved solubility and specificity [110] . Accordingly, several patents exploiting Hsp90 inhibition have surfaced in the past two years [112] [113] [114] .
Patient selection also plays an important role in targeted therapeutics; patients with a B-Raf V600E mutation are more likely to derive clinical benefit than those with wild-type B-Raf, therefore mutation analysis is an important component of screening prior to clinical trial entry. Additional new patents are aimed at determining which patients will respond to therapy [115, 116] .
Important advances have been achieved in expanding our knowledge of how to make highly potent and selective MAPK pathway inhibitors. More drugs are currently in the pipeline, such as GDC-0879, GDC-0623, AZD8330, RO5126766, RO5212054, RO5068760, and PD318088. These drugs all promise increased potency and specificity, with less toxicity. The clinical oncology field will be anxious to evaluate these and other B-Raf and MEK inhibitors, and other MAPK inhibitors, including those targeting ERK, which were reported in recent patent applications [66, [117] [118] [119] [120] [121] [122] [123] [124] . Although there is still a paucity of published data, the novel ERK inhibitors AEZS-131 (AEterna Zentaris, Frankfurt, Germany) and SCH772984 (Bayer Schering Pharma, Pittsburgh, PA) are currently in preclinical evaluation. Determining which cancer patients will receive the most benefit and with what regimens or combinations of inhibitors targeting multiple pathways to overcome drug resistance will be a challenge as we move forward to more individualized cancer therapies.
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